High-density lipoprotein metabolism in human apolipoprotein B100transgenic/brown adipose tissue deficient mice: A model of obesity-induced hyperinsulinemia

Applied Physiology, Nutrition and Metabolism

Volumn 36, Issue 3, 2011, Pages 313-322

  Ehlers, Sarah J ^a   Larson, Stephanie M ^a   Rasmussen, Heather E ^a   Park, Young Ki ^a   Lee, Ji Young ^a  

^a UNIVERSITY OF NEBRASKA LINCOLN   (United States)

Author keywords

ATP binding cassette transporter A I; HApoBtg BATless mice; High density lipoprotein cholesterol; Insulin resistance; Obesity

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER A1; APOLIPOPROTEIN B100; HIGH DENSITY LIPOPROTEIN; INSULIN; LIPID;

ANIMAL; ARTICLE; BLOOD; BROWN ADIPOSE TISSUE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; HYPERINSULINISM; LIVER; MALE; METABOLISM; MOUSE; MOUSE MUTANT; OBESITY; PHYSIOLOGY; TRANSGENIC MOUSE;

ADIPOSE TISSUE, BROWN; ANIMALS; APOLIPOPROTEIN B-100; ATP-BINDING CASSETTE TRANSPORTERS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; HYPERINSULINISM; INSULIN; LIPIDS; LIPOPROTEINS, HDL; LIVER; MALE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; OBESITY;

EID: 79956360003     PISSN: 17155312     EISSN: 17155320     Source Type: Journal    
DOI: 10.1139/h11-003     Document Type: Article

References (57)

1. Acton, S., Rigotti, A., Landschulz, K.T., Xu, S., Hobbs, H.H., and Krieger, M. 1996. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science, 271(5248): 518-520. doi:10.1126/science.271.5248.518. PMID:8560269.
2. Attie, A.D. 2007. ABCA1: at the nexus of cholesterol, HDL and atherosclerosis. Trends Biochem. Sci. 32(4): 172-179. doi:10. 1016/j.tibs.2007.02.001. PMID:17324574.
3. Biesbroeck, R.C., Albers, J.J., Wahl, P.W., Weinberg, C.R., Bassett, M.L., and Bierman, E.L. 1982. Abnormal composition of high density lipoproteins in non-insulin-dependent diabetics. Diabetes, 31(2): 126-131. PMID:6818072.
4. Brewer, H.B., Jr, Remaley, A.T., Neufeld, E.B., Basso, F., and Joyce, C. 2004. Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 24(10): 1755-1760. doi:10.1161/01.ATV. 0000142804.27420.5b. PMID:15319263.
5. Brinton, E.A., Eisenberg, S., and Breslow, J.L. 1991. Increased apo A-I and apo A-II fractional catabolic rate in patients with low high density lipoprotein-cholesterol levels with or without hypertriglyceridemia. J. Clin. Invest. 87(2): 536-544. doi:10.1172/JCI115028. PMID:1899429.
6. Briones, E.R., Mao, S.J., Palumbo, P.J., O'Fallon, W.M., Chenoweth, W., and Kottke, B.A. 1984. Analysis of plasma lipids and apolipoproteins in insulin-dependent and noninsulin-dependent diabetics. Metabolism, 33(1): 42-49. doi:10.1016/0026-0495(84)90160-4. PMID:6419012.
7. Brunham, L.R., Kruit, J.K., Iqbal, J., Fievet, C., Timmins, J.M., Pape, T.D., et al. 2006. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J. Clin. Invest. 116(4): 1052-1062. doi:10. 1172/JCI27352. PMID:16543947.
8. Callow, M.J., Stoltzfus, L.J., Lawn, R.M., and Rubin, E.M. 1994. Expression of human apolipoprotein B and assembly of lipoprotein (a) in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 91(6): 2130-2134. doi:10.1073/pnas.91.6.2130. PMID:8134359.
9. De Lorgeril, M. 2007. Essential polyunsaturated fatty acids, inflammation, atherosclerosis and cardiovascular diseases. Subcell. Biochem. 42: 283-297. doi:10.1007/1-4020-5688-5_13. PMID:17612056.
10. Francis, G.A., Knopp, R.H., and Oram, J.F. 1995. Defective removal of cellular cholesterol and phospholipids by apolipoprotein A-I in Tangier Disease. J. Clin. Invest. 96(1): 78-87. doi:10.1172/JCI118082. PMID:7615839.
11. Francone, O.L., Subbaiah, P.V., van Tol, A., Royer, L., and Haghpassand, M. 2003. Abnormal phospholipid composition impairs HDL biogenesis and maturation in mice lacking Abca1. Biochemistry, 42(28): 8569-8578. doi:10.1021/bi034540v.PMID:12859204.
12. Frénais, R., Ouguerram, K., Maugeais, C., Mahot, P., Maugere, P., Krempf, M., and Magot, T. 1997. High density lipoprotein apolipoprotein AI kinetics in NIDDM: a stable isotope study. Diabetologia, 40(5): 578-583. doi:10.1007/s001250050718.PMID:9165227.
13. Gordon, T., Castelli, W.P., Hjortland, M.C., Kannel, W.B., and Dawber, T.R. 1977. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am. J. Med. 62(5): 707-714. doi:10.1016/0002-9343(77)90874-9.PMID:193398.
14. Gordon, D.J., Probstfield, J.L., Garrison, R.J., Neaton, J.D., Castelli, W.P., Knoke, J.D., et al. 1989. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation, 79(1): 8-15. PMID:2642759.
15. Grundy, S.M., Howard, B., Smith, S., Jr, Eckel, R., Redberg, R., and Bonow, R.O. 2002. Prevention Conference VI: Diabetes and Cardiovascular Disease: executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation, 105(18): 2231-2239. doi:10.1161/01.CIR.0000013952.86046.DD. PMID:11994261.
16. Howard, B.V., Rodriguez, B.L., Bennett, P.H., Harris, M.I., Hamman, R., Kuller, L.H., et al. 2002. Prevention Conference VI: Diabetes and Cardiovascular disease: Writing Group I: epidemiology. Circulation, 105(18): e132-e137. doi:10.1161/01.CIR.0000013953.41667.09. PMID:11994263.
17. Huuskonen, J., Olkkonen, V.M., Jauhiainen, M., and Ehnholm, C. 2001. The impact of phospholipid transfer protein (PLTP) on HDL metabolism. Atherosclerosis, 155(2): 269-281. doi:10.1016/S0021-9150(01)00447-6. PMID:11254896.
18. Jiang, X., Francone, O.L., Bruce, C., Milne, R., Mar, J., Walsh, A., et al. 1996. Increased preb-high density lipoprotein, apolipoprotein AI, and phospholipid in mice expressing the human phospholipids transfer protein and human apolipoprotein AI transgenes. J. Clin. Invest. 98(10): 2373-2380. doi:10.1172/JCI119050. PMID:8941656.
19. Jiang, X.C., Bruce, C., Mar, J., Lin, M., Ji, Y., Francone, O.L., and Tall, A.R. 1999. Targeted mutation of plasma phospholipids transfer protein gene markedly reduces high-density lipoprotein levels. J. Clin. Invest. 103(6): 907-914. doi:10.1172/JCI5578.PMID:10079112.
20. Kozarsky, K.F., Donahee, M.H., Rigotti, A., Iqbal, S.N., Edelman, E.R., and Krieger, M. 1997. Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels. Nature, 387 (6631): 414-417. doi:10.1038/387414a0. PMID:9163428.
21. Krauss, R.M. 2004. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care, 27(6): 1496-1504. doi:10.2337/diacare. 27.6.1496. PMID:15161808.
22. Krieger, M. 1998. The "best" of cholesterols, the "worst" of cholesterols: a tale of two receptors. Proc. Natl. Acad. Sci. U.S.A. 95(8): 4077-4080. doi:10.1073/pnas.95.8.4077. PMID:9539689.
23. Krieger, M. 1999. Charting the fate of the "good cholesterol": identification and characterization of the high-density lipoprotein receptor SR-BI. Annu. Rev. Biochem. 68(1): 523-558. doi:10.1146/annurev.biochem.68.1.523. PMID:10872459.
24. Le, N.A., and Ginsberg, H.N. 1988. Heterogeneity of apolipoprotein A-I turnover in subjects with reduced concentrations of plasma high density lipoprotein cholesterol. Metabolism, 37(7): 614-617. doi:10.1016/0026-0495(88)90077-7. PMID:3133537.
25. Lee, J.Y., and Parks, J.S. 2005. ATP-binding cassette transporter AI and its role in HDL formation. Curr. Opin. Lipidol. 16(1): 19-25. doi:10.1097/00041433-200502000-00005. PMID:15650559.
26. Lee, J.Y., Timmins, J.M., Mulya, A., Smith, T.L., Zhu, Y., Rubin, E.M., et al. 2005. HDLs in apoA-I transgenic Abca1 knockout mice are remodeled normally in plasma but are hypercatabolized by the kidney. J. Lipid Res. 46(10): 2233-2245. doi:10.1194/jlr.M500179-JLR200. PMID:16024913.
27. Lewis, G.F., and Rader, D.J. 2005. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ. Res. 96(12): 1221-1232. doi:10.1161/01.RES.0000170946.56981.5c.PMID:15976321.
28. Linton, M.F., Farese, R.V., Jr, Chiesa, G., Grass, D.S., Chin, P., Hammer, R.E., et al. 1993. Transgenic mice expressing high plasma concentrations of human apolipoprotein B100 and lipoprotein(a). J. Clin. Invest. 92(6): 3029-3037. doi:10.1172/JCI116927. PMID:8254057.
29. Lowell, B.B., S-Susulic, V., Hamann, A., Lawitts, J.A., Himms-Hagen, J., Boyer, B.B., et al. 1993. Development of obesity in transgenic mice after genetic ablation of brown adipose tissue. Nature, 366(6457): 740-742. doi:10.1038/366740a0. PMID:8264795.
30. McNeish, J., Aiello, R.J., Guyot, D., Turi, T., Gabel, C., Aldinger, C., et al. 2000. High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1. Proc. Natl. Acad. Sci. U.S.A. 97(8): 4245-4250. doi:10.1073/pnas.97.8.4245. PMID:10760292.
31. Moore, R.E., Navab, M., Millar, J.S., Zimetti, F., Hama, S., Rothblat, G.H., and Rader, D.J. 2005. Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation. Circ. Res. 97(8):763-771. doi:10.1161/01.RES.0000185320.82962.F7. PMID:16151025.
32. Mulya, A., Lee, J.Y., Gebre, A.K., Thomas, M.J., Colvin, P.L., and Parks, J.S. 2007. Minimal lipidation of pre-beta HDL by ABCA1 results in reduced ability to interact with ABCA1. Arterioscler. Thromb. Vasc. Biol. 27(8): 1828-1836. doi:10.1161/ATVBAHA.107.142455.PMID:17510466.
33. Mulya, A., Lee, J.-Y., Gebre, A.K., Boudyguina, E.Y., Chung, S.-K., Smith, T.L., et al. 2008. Initial interaction of apoA-I with ABCA1 impacts in vivo metabolic fate of nascent HDL. J. Lipid Res. 49(11): 2390-2401. doi:10.1194/jlr.M800241-JLR200.PMID:18583707.
34. Nishina, P.M., Lowe, S., Wang, J., and Paigen, B. 1994. Characterization of plasma lipids in genetically obese mice: the mutants obese, diabetes, fat, tubby, and lethal yellow. Metabolism, 43(5): 549-553. doi:10.1016/0026-0495(94)90194-5.PMID:8177042.
35. Ooi, E.M., Watts, G.F., Farvid, M.S., Chan, D.C., Allen, M.C., Zilko, S.R., and Barrett, P.H.R. 2005. High-density lipoprotein apolipoprotein A-I kinetics in obesity. Obes. Res. 13(6): 1008-1016. doi:10.1038/oby.2005.118. PMID:15976143.
36. Oram, J.F. 2000. Tangier disease and ABCA1. Biochim. Biophys. Acta, 1529(1-3): 321-330.
37. Park, Y.-K., Rasmussen, H.E., Ehlers, S.J., Blobaum, K.R., Lu, F., Schlegal, V.L., et al. 2008. Repression of proinflammatory gene expression by lipid extract of Nostoc commune var sphaeroides Kutzing, a blue-green alga, via inhibition of nuclear factor-k B in RAW 264.7 macrophages. Nutr. Res. 28(2): 83-91. doi:10.1016/j.nutres.2007.11.008. PMID:19083393.
38. Perségol, L., Vergès, B., Gambert, P., and Duvillard, L. 2007. Inability of HDL from abdominally obese subjects to counteract the inhibitory effect of oxidized LDL on vasorelaxation. J. Lipid Res. 48(6): 1396-1401. doi:10.1194/jlr.M600309-JLR200. PMID:17329618.
39. Rader, D.J. 2006. Molecular regulation of HDL metabolism and function: implications for novel therapies. J. Clin. Invest. 116(12): 3090-3100. doi:10.1172/JCI30163.MID:17143322.
40. Rader, D.J., Ikewaki, K., Duverger, N., Schmidt, H., Pritchard, H., Frohlich, J., et al. 1994. Markedly accelerated catabolism of apolipoprotein A-II (ApoA-II) and high density lipoproteins containing ApoA-II in classic lecithin: cholesterol acyltransferase deficiency and fish-eye disease. J. Clin. Invest. 93(1): 321-330. doi:10.1172/JCI116962.MID:8282802.
41. Ragozin, S., Niemeier, A., Laatsch, A., Loeffler, B., Merkel, M., Beisiegel, U., and Heeren, J. 2005. Knockdown of hepatic ABCA1 by RNA interference decreases plasma HDL cholesterol levels and influences postprandial lipemia in mice. Arterioscler. Thromb. Vasc. Biol. 25(7): 1433-1438. doi:10.1161/01.ATV.0000166616.86723.d0. PMID:15845910.
42. Rasmussen, H.E., Blobaum, K.R., Park, Y.K., Ehlers, S.J., Lu, F., and Lee, J.Y. 2008. Lipid extract of Nostoc commune var. sphaeroides Kutzing, a blue-green alga, inhibits the activation of sterol regulatory element binding proteins in HepG2 cells. J. Nutr. 138(3): 476-481. PMID:18287352.
43. Rasmussen, H.E., Blobaum, K.R., Jesch, E.D., Ku, C.S., Park, Y.K., Lu, F., et al. 2009. Hypocholesterolemic effect of Nostoc commune var. sphaeroides Kutzing, an edible blue-green alga. Eur. J. Nutr. 48(7): 387-394. doi:10.1007/s00394-009-0025-y.PMID:19404563.
44. Rogler, G., Trumbach, B., Klima, B., Lackner, K.J., and Schmitz, G. 1995. HDL-mediated efflux of intracellular cholesterol is impaired in fibroblasts from Tangier disease patients. Arterioscler. Thromb. Vasc. Biol. 15(5): 683-690. PMID:7749882.
45. Salmon, D.M., and Hems, D.A. 1973. Plasma lipoproteins and the synthesis and turnover of plasma triglyceride in normal and genetically obese mice. Biochem. J. 136(3): 551-563. PMID:4360712.
46. Sasahara, T., Yamashita, T., Sviridov, D., Fidge, N., and Nestel, P. 1997. Altered properties of high density lipoprotein subfractions in obese subjects. J. Lipid Res. 38(3): 600-611. PMID:9101441.
47. Sasahara, T., Nestel, P., Fidge, N., and Sviridov, D. 1998. Cholesterol transport between cells and high density lipoprotein subfractions from obese and lean subjects. J. Lipid Res. 39(3): 544-554. PMID: 9548587.
48. Schaefer, E.J., Zech, L.A., Jenkins, L.L., Bronzert, T.J., Rubalcaba, E.A., Lindgren, F.T., et al. 1982. Human apolipoprotein A-I and A-II metabolism. J. Lipid Res. 23(6): 850-862. PMID:6813411.
49. Schreyer, S.A., Hart, L.K., and Attie, A.D. 1994. Hypercatabolism of lipoprotein-free apolipoprotein A-I in HDL-deficient mutant chickens. Arterioscler. Thromb. 14(12): 2053-2059. PMID: 7981195.
50. Singaraja, R.R., Van Eck, M., Bissada, N., Zimetti, F., Collins, H.L., Hildebrand, R.B., et al. 2006. Both hepatic and extrahepatic ABCA1 have discrete and essential functions in the maintenance of plasma high-density lipoprotein cholesterol levels in vivo. Circulation, 114(12): 1301-1309. doi:10.1161/CIRCULATIONAHA.106.621433. PMID:16940190.
51. Siri, P., Candela, N., Zhang, Y.L., Ko, C., Eusufzai, S., Ginsberg, H.N., and Huang, L.S. 2001. Post-transcriptional stimulation of the assembly and secretion of triglyceride-rich apolipoprotein B lipoproteins in a mouse with selective deficiency of brown adipose tissue, obesity, and insulin resistance. J. Biol. Chem. 276(49): 46064-46072. doi:10.1074/jbc.M108909200.PMID:11598138.
52. Timmins, J.M., Lee, J.Y., Boudyguina, E., Kluckman, K.D., Brunham, L.R., Mulya, A., et al. 2005. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J. Clin. Invest. 115(5): 1333-1342. PMID:15841208.
53. Van Gaal, L.F., Mertens, I.L., and De Block, C.E. 2006. Mechanisms linking obesity with cardiovascular disease. Nature, 444(7121): 875-880. doi:10.1038/nature05487.PMID:17167476.
54. Wang, Y., and Oram, J.F. 2002. Unsaturated fatty acids inhibit cholesterol efflux from macrophages by increasing degradation of ATP-binding cassette transporter A1. J. Biol. Chem. 277(7): 5692-5697. doi:10.1074/jbc.M109977200. PMID:11741998.
55. Wang, Y., and Oram, J.F. 2005. Unsaturated fatty acids phosphorylate and destabilize ABCA1 through a phospholipase D2 pathway. J. Biol. Chem. 280(43): 35896-35903. doi:10.1074/jbc.M506210200. PMID:16118212.
56. Wang, Y., and Oram, J.F. 2007. Unsaturated fatty acids phosphorylate and destabilize ABCA1 through a protein kinase C δ pathway. J. Lipid Res. 48(5): 1062-1068. doi:10.1194/jlr.M600437-JLR200. PMID:17325386.
57. Wendt, T., Bucciarelli, L., Qu, W., Lu, Y., Yan, S.F., Stern, D.M., and Schmidt, A.M. 2002. Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes. Curr. Atheroscler. Rep. 4(3): 228-237. doi:10.1007/s11883-002-0024-4.PMID:11931721.